| Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, ... New England Journal of Medicine 378 (8), 731-739, 2018 | 2583 | 2018 |
| Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials DS Hong, SG DuBois, S Kummar, AF Farago, CM Albert, KS Rohrberg, ... The Lancet Oncology 21 (4), 531-540, 2020 | 819 | 2020 |
| Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies S Kummar, R Kinders, ME Gutierrez, L Rubinstein, RE Parchment, ... Journal of clinical oncology 27 (16), 2705-2711, 2009 | 388 | 2009 |
| Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors K Do, D Wilsker, J Ji, J Zlott, T Freshwater, RJ Kinders, J Collins, AP Chen, ... Journal of Clinical Oncology 33 (30), 3409-3415, 2015 | 328 | 2015 |
| Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas S Kummar, A Chen, J Ji, Y Zhang, JM Reid, M Ames, L Jia, M Weil, ... Cancer research 71 (17), 5626-5634, 2011 | 303 | 2011 |
| Wee1 kinase as a target for cancer therapy K Do, JH Doroshow, S Kummar Cell cycle 12 (19), 3348-3353, 2013 | 287 | 2013 |
| SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study A Ribas, T Medina, S Kummar, A Amin, A Kalbasi, JJ Drabick, M Barve, ... Cancer discovery 8 (10), 1250-1257, 2018 | 282 | 2018 |
| Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements S Kummar, HX Chen, J Wright, S Holbeck, MD Millin, J Tomaszewski, ... Nature reviews Drug discovery 9 (11), 843-856, 2010 | 272 | 2010 |
| Using cereal grain winter cover crops to reduce groundwater nitrate contamination in the mid-Atlantic coastal plain KW Staver, RB Brinsfield Journal of Soil and Water Conservation 53 (3), 230-240, 1998 | 260 | 1998 |
| Compressing drug development timelines in oncology using phase'0'trials S Kummar, R Kinders, L Rubinstein, RE Parchment, AJ Murgo, J Collins, ... Nature Reviews Cancer 7 (2), 131-139, 2007 | 259 | 2007 |
| Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer L Fong, A Hotson, JD Powderly, M Sznol, RS Heist, TK Choueiri, ... Cancer discovery 10 (1), 40-53, 2020 | 253 | 2020 |
| Clinicopathologic Features of Non–Small-Cell Lung Cancer Harboring an NTRK Gene Fusion AF Farago, MS Taylor, RC Doebele, VW Zhu, S Kummar, AI Spira, ... JCO precision oncology 2, 1-12, 2018 | 237 | 2018 |
| Cediranib for metastatic alveolar soft part sarcoma S Kummar, D Allen, A Monks, EC Polley, CD Hose, SP Ivy, IB Turkbey, ... Journal of Clinical Oncology 31 (18), 2296-2302, 2013 | 233 | 2013 |
| A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas S Kummar, J Ji, R Morgan, HJ Lenz, SL Puhalla, CP Belani, DR Gandara, ... Clinical cancer research 18 (6), 1726-1734, 2012 | 232 | 2012 |
| Primary non-Hodgkin's lymphoma of the liver V Noronha, NQ Shafi, JA Obando, S Kummar Critical reviews in oncology/hematology 53 (3), 199-207, 2005 | 232 | 2005 |
| Drug development in oncology: classical cytotoxics and molecularly targeted agents S Kummar, M Gutierrez, JH Doroshow, AJ Murgo British journal of clinical pharmacology 62 (1), 15-26, 2006 | 212 | 2006 |
| Introduction to population pharmacokinetic/pharmacodynamic analysis with nonlinear mixed effects models JS Owen, J Fiedler-Kelly John Wiley & Sons, 2014 | 202 | 2014 |
| A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors A Rajan, CA Carter, RJ Kelly, M Gutierrez, S Kummar, E Szabo, ... Clinical cancer research 18 (8), 2344-2351, 2012 | 190 | 2012 |
| Clinical activity of the γ-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis) S Kummar, G O'Sullivan Coyne, KT Do, B Turkbey, PS Meltzer, E Polley, ... Journal of Clinical Oncology 35 (14), 1561-1569, 2017 | 186 | 2017 |
| Advances in using PARP inhibitors to treat cancer S Kummar, A Chen, RE Parchment, RJ Kinders, J Ji, JE Tomaszewski, ... BMC medicine 10, 1-5, 2012 | 177 | 2012 |
